Beacon gene therapy VISTA trial reports positive results for X-linked retinitis pigmentosapositive results for X-linked retinitis pigmentosa
Beacon Therapeutics has announced positive results from its phase 2/3 VISTA trial of laru-zova, an experimental gene therapy for X-linked retinitis pigmentosa (XLRP). The findings mark a significant step forward for a condition that currently has no approved treatments.